Cambrex Expands Biopharmaceutical Services Business01 March 2022
East Rutherford, NJ – March 1, 2022 – Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business. The expansion includes 11 additional cGMP laboratories at Cambrex's Durham, NC facility and broadens its service offering for large molecule and viral/cell-based therapeutics.
"We are excited to be adding to our fast-growing biopharmaceutical services business," said Cambrex CEO Thomas Loewald. "Building upon the strength of our analytical team in Durham, this expansion enables us to increase our capacity to serve the large and growing biologics market, supporting the development and testing of a rapidly growing pipeline of large molecule therapeutics."
The expansion includes a range of new instruments supporting nanoparticle size analysis, imaging, qPCR, fluorescent/absorbance plate readers, immunoblotting, mass spectrometry, next-generation sequencing (NGS), chromatography capillary electrophoresis (CE-PDA and FLD), SEC-MALS, and other compendial testing.
These new capabilities apply to a wide variety of biopharmaceutical therapeutics, including bacteriophage and mammalian viruses, recombinant proteins, monoclonal antibodies, and nucleic acids. Additionally, Cambrex recently installed a new 600 MHz NMR spectrometer to enhance support for both biopharmaceutical and small molecule programs. Combining these new capabilities with their existing services, Cambrex is now positioned to provide analytical services throughout the lifecycle of small and large molecule therapeutics.